Mostrar el registro sencillo del ítem

dc.contributor.authorFernández Ochoa, Álvaro 
dc.contributor.authorBorras Linares, María Isabel 
dc.contributor.authorQuirantes-Piné, Rosa
dc.contributor.authorPRECISESADS Clinical Consortium
dc.contributor.authorAlarcón Riquelme, Marta Eugenia 
dc.contributor.authorBeretta, Lorenzo
dc.contributor.authorSegura Carretero, Antonio 
dc.date.accessioned2025-03-19T12:46:19Z
dc.date.available2025-03-19T12:46:19Z
dc.date.issued2019-11-20
dc.identifier.citationPublished version: Fernández Ochoa, Álvaro et al. Journal of Pharmaceutical and Biomedical Analysis Volume 179, 5 February 2020, 112999. https://doi.org/10.1016/j.jpba.2019.112999es_ES
dc.identifier.urihttps://hdl.handle.net/10481/103190
dc.descriptionThe work described has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement No. 115565, the resources for which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in-kind contribution. We thank all the members of PRECISESADS Clinical Consortium (Table 6S) for their effort in the sample recruitment, distribution and assessment of the samples used in this study. The author AFO gratefully acknowledges the Spanish Ministry of Education, Culture and Sports for the FPU grant (FPU14/03992).es_ES
dc.description.abstractSjögren’s Syndrome (SjS) is a complex autoimmune disease characterized by the affection of the exocrine glands and the involvement of multiple organs. Although a greater number of biomarker studies have been carried out in recent years, the origin and pathogenesis are not yet well known and therefore there is a need to continue studying this pathology. This work aims to find metabolic changes in biological samples (plasma and urine), which could help identify the metabolic pathways affected by the SjS pathogenesis. The samples collected from SjS patients and healthy volunteers were analyzed by a fingerprinting metabolomic approach based on HPLC-ESI-QTOF-MS methodology. After feature pre-selection by univariate statistical tests, an integrated PLS-DA model using data from urine and plasma was constructed obtaining a good classification between cases and controls (AUROC = 0.839 ± 0.021). 31 and 38 metabolites in plasma and urine, respectively, showed significant differences between healthy volunteers and SjS patients and were proposed for their identification. From them, 12 plasma and 24 urinary metabolites could be annotated. In general, the main metabolic pathways altered in SjS patients were related to the metabolism of phospholipids, fatty acids, and amino acids, specially tryptophan, proline and phenylalanine.es_ES
dc.description.sponsorshipEuropean Union’s Seventh Framework Programme (FP7/2007-2013) 115565es_ES
dc.description.sponsorshipEuropean Federation of Pharmaceutical Industries and Associations (EFPIA)es_ES
dc.description.sponsorshipSpanish Ministry of Education, Culture and Sports (FPU14/03992)es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectMetabolomicses_ES
dc.subjectHPLC-ESI-QTOF-MSes_ES
dc.subjectSjögren’s Syndromees_ES
dc.subjectbiomarkerses_ES
dc.subjectunsaturated fatty acidses_ES
dc.subjectphosphatidylinositolses_ES
dc.titleDiscovering new metabolite alterations in primary Sjögren’s Syndrome in urinary and plasma samples using an HPLC-ESI-QTOF-MS methodologyes_ES
dc.typejournal articlees_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/115565es_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1016/j.jpba.2019.112999
dc.type.hasVersionSMURes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional